- Home
- PEN vs EXEL Comparison
PEN vs EXEL Comparison
Compare PEN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- EXEL
- Stock Information
- Founded
- PEN 2004
- EXEL 1994
- Country
- PEN United States
- EXEL United States
- Employees
- PEN N/A
- EXEL N/A
- Industry
- PEN Medical/Dental Instruments
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEN Health Care
- EXEL Health Care
- Exchange
- PEN Nasdaq
- EXEL Nasdaq
- Market Cap
- PEN 10.5B
- EXEL 9.8B
- IPO Year
- PEN 2015
- EXEL 2000
- Fundamental
- Price
- PEN $297.46
- EXEL $36.17
- Analyst Decision
- PEN Strong Buy
- EXEL Buy
- Analyst Count
- PEN 16
- EXEL 18
- Target Price
- PEN $299.73
- EXEL $37.59
- AVG Volume (30 Days)
- PEN 543.6K
- EXEL 2.2M
- Earning Date
- PEN 04-23-2025
- EXEL 05-13-2025
- Dividend Yield
- PEN N/A
- EXEL N/A
- EPS Growth
- PEN N/A
- EXEL 170.77
- EPS
- PEN 1.08
- EXEL 1.76
- Revenue
- PEN $1,240,100,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- PEN $14.26
- EXEL $5.78
- Revenue Next Year
- PEN $14.21
- EXEL $10.94
- P/E Ratio
- PEN $277.28
- EXEL $20.64
- Revenue Growth
- PEN 13.17
- EXEL 18.50
- 52 Week Low
- PEN $148.00
- EXEL $20.14
- 52 Week High
- PEN $310.00
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- PEN 60.78
- EXEL 43.89
- Support Level
- PEN $285.27
- EXEL $34.90
- Resistance Level
- PEN $296.44
- EXEL $40.26
- Average True Range (ATR)
- PEN 10.39
- EXEL 1.21
- MACD
- PEN 0.15
- EXEL -0.19
- Stochastic Oscillator
- PEN 70.40
- EXEL 23.69
About PEN Penumbra Inc.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.